Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hoth Therapeutics ( (HOTH) ) has provided an announcement.
Hoth Therapeutics has announced the development of HT-001, a topical gel designed to treat cutaneous toxicities caused by EGFR inhibitors used in cancer treatment. Preclinical studies and preliminary data from an ongoing Phase 2a study show promising results, with significant reductions in skin toxicities and maintenance of cancer treatment efficacy. This development positions Hoth Therapeutics as a pioneer in addressing a significant unmet need in oncology, potentially improving patient outcomes and offering a novel solution for managing dermatological side effects in cancer patients.
The most recent analyst rating on (HOTH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is primarily engaged in creating treatments for dermatological conditions, particularly those induced by cancer therapies, such as epidermal growth factor receptor inhibitors (EGFRIs).
Average Trading Volume: 1,189,264
Technical Sentiment Signal: Buy
Current Market Cap: $15.98M
Learn more about HOTH stock on TipRanks’ Stock Analysis page.